Background: To assess the efficacy of neoadjuvant chemotherapy (NAC) in esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy (CRT). Methods: The clinical data of patients with ESCC treated with chemoradiotherapy with or without NAC were collected and retrospectively reviewed. The overall survival, locoregional failure-free survival, and distant failure-free survival were analyzed statistically. Results: A total of 60 patients fulfilled the inclusion criteria, of which 41 were treated with NAC-CRT and 19 were treated with CRT-alone. Patient characteristics were well balanced between the NAC-CRT and CRT-alone groups, except for the ECOG scores. The tumor response to NAC included 11 patients (26.8%) with partial response (PR), 25 patients (61.0%) with stable disease (SD), 5 patients (12.2%) with progression disease (PD), and no patients with complete response (CR). After CRT, 21 patients achieved CR (14 after NAC-CRT and 7 after CRTalone), 30 had PR (19 and 11, respectively), 6 maintained SD (5 and 1, respectively), and 3 patients (all in the NAC-CRT group) developed PD. Twenty-nine patients (18 in NAC-CRT and 11 in CRT-alone) succumbed to the disease from locoregional or distant failure, one patient in the NAC-CRT group died of radiation pneumonitis, one patient in the CRT-alone group died from unknown reasons, and 29 patients remained alive. The overall survival, locoregional failure-free survival, and distant failure-free survival at 1 and 2 years in all the patients were 64.9% and 40.5%, 58.6% and 52.0%, and 85.7% and 79.3%, respectively. The overall survival, locoregional failure-free survival, and distant failure-free survival between the NAC-CRT group and the CRT-alone group were not significantly different. Conclusion: In patients with ESCC treated with definitive CRT, NAC treatment using the current regimen does not prolong overall survival, locoregional failure-free survival or distant failure-free survival. Further development of NAC treatment is urgently needed.
Introduction
Esophageal carcinoma is a devastating malignancy which is the 4th leading cause of cancer deaths in China 1 in which squamous cell cancer was the predominant pathology type. More than 40% of patients are not candidates for surgery because of the advanced stage of their cancer or concomitant diseases at diagnosis. 2 Definitive chemoradiotherapy (CRT) is regarded as the standard treatment for inoperable esophageal cancer patients. 3 However, even with the continuing development of radiotherapy technology and chemotherapy regimens, the 5-year survival of patients treated with CRT is still poor, at about 20%.
Neoadjuvant chemotherapy (NAC) is hypothesized to reduce the tumor volume, eliminate micrometastasis, ameliorate dysphagia, test for the effect of chemotherapy in vivo, and promote a survival benefit. 5 NAC was first reported by Kelsen et al. 6 and has stimulated many further investigations that have established its use in patients with operable locally advanced esophageal cancer. 7e9 Byfield and colleagues conducted the first clinical trial of induction chemotherapy followed with radiotherapy alone in esophageal cancer patients in the 1980s, which produced encouraging results. 10 However, despite the fact that NAC had been used in several previous clinical trial protocols, 11e13 the efficacy of NAC in esophageal squamous cell carcinoma (ESCC) patients treated with CRT has rarely been reported, and the results that have been reported are contradictory. 14e18 In the present study, the clinical data of ESCC patients treated with CRT-alone and CRT with NAC (NAC-CRT) were retrospectively reviewed to assess the efficacy of NAC.
Methods

Pretreatment workup and eligibility criteria
This retrospective analysis was approved by Fujian Medical University Union Hospital Institutional Review Board (No. 2016KY001). All patients signed an informed consent prior to treatment, and all information was anonymized and deidentified prior to its analysis.
The eligibility and exclusion criteria for this retrospective study were as follows: initial histologically-proven esophageal squamous cell carcinoma, clinical stage of T any N any M 0 or M 1 with supraclavicular lymph node metastasis, good performance status (Eastern Cooperative Oncology Group scoring, ECOG, 2), completion of the CRT treatment schema without adjuvant chemotherapy or salvage surgery/endoscopic resection, completion of a pretreatment workup and follow-up data, and without other concomitant medical conditions that required treatment.
The pretreatment workup included taking the patients' medical history, assessment of swallowing function, physical examination, standard laboratory tests, esophagogastroduodenoscopy, barium esophagography, cervical and abdominal ultrasound, and chest computed tomography (CT). Bone scan or magnetic resonance imaging or bronchoscopy was performed if it was considered necessary. The clinical TNM stage was determined according to the 7th AJCC TNM staging system 19 based on the CT scan findings. 20 
Neoadjuvant and concurrent chemotherapy
The regimens of neoadjuvant and concurrent chemotherapy in the current study included a single regimen of platinum or fluorouracil or Capecitabine and combined regimens of platinum plus fluorouracil or platinum plus taxane. Only under conditions of disease progression during or after NAC will the chemotherapy regimens between neoadjuvant and concurrent differ. The adjustment of the neoadjuvant and concurrent chemotherapy time interval and dose intensity was reported in our previous study. 21 
Radiotherapy
Radiotherapy used 3-dimensional conformal or intensity modulated radiation therapy technology. In patients treated with NAC-CRT, radiotherapy would normally be initiated 3 weeks after completion of the latest neoadjuvant chemotherapy. The targets of radiotherapy were defined and contoured as previously published. 21, 22 The gross tumor volume (GTV) contains the primary tumor and metastatic lymph nodes. The clinical target volume (CTV) was defined as the primary tumor with a margin of 3.0 cm in the cranial-caudal directions (and a minimum of 1.0 cm for the lymph nodes), a 0.5-cm margin (modified for anatomic boundaries) circumferentially, and the elective lymph nodal regions. The doses to the CTV and GTV were 4000e5040 cGy and 5040e6600 cGy (180e220 cGy/fractions), respectively.
The dose limitations of the organ at risk were as follows. The D max (maximum dose) for the spinal cord was less than 4500 cGy. The D mean (mean dose) for the lung was <1800 cGy, V 20 and V 5 (volumes receiving >2000 cGy and >500 cGy, respectively) were <27% and <70%, respectively. The V 45 of the heart was <60%. For the liver, the V 30 was <60% and the D mean was <3000 cGy. If dose limitations for any one of the organs at risk could not be satisfied, the radiotherapy was applied to the gross tumor only. There were a total of seven patients in the current study who received only GTV radiotherapy.
Criteria for toxicity and treatment response
The chemotherapy toxicities were graded using the National Cancer Institute common toxicity criteria (NCI CTC v 3.0). 26 The acute RT toxicities were assessed with the RTOG. 27 The clinical criteria for tumor response were defined by RECIST1.1, 28 and were based on the findings of CT scanning and barium esophagography. A clinically complete response (CR) was defined as no evidence of disease on imaging and negative by endoscopic biopsy; a partial response (PR) was defined as a 30% or greater decrease in tumor maximum dimension; stable disease (SD) was defined as a less than 30% decrease or increase 20% and no evidence of metastatic disease. Progression of disease (PD) was defined as a 20% or greater increase or development of distant metastatic disease. The objective tumor response (overall response, OR) included the patients with CR and PR.
The response to treatment was evaluated by CT scanning, barium esophagography and esophagogastroduodenoscopy if needed. The time to evaluation was at 3e4 weeks after the completion of treatment and reassessed after at least 4 weeks.
Follow-up and statistical analysis
Patients were evaluated every 3 months for the first two years after CRT, every 6 months for the next three years, and then annually. Surveillance included reviewing the interim history and physical examination, assessment of swallowing function, performance status and weight measurement, and laboratory testing. Esophagogastroduodenoscopy and CT of the chest and abdomen were performed every 6 months for two years and performed annually thereafter. 21 All patient outcomes were evaluated in October 2016. The primary outcomes of interest were OS, LFFS, and DFFS. Secondary endpoints were tumor response. Overall survival was calculated from the diagnosis day to the date of death or the last follow-up. LFFS and DFFS were defined as the time from the day of diagnosis to local and/or regional and distant progression, respectively.
The data were analyzed with SPSS software, version 18.0 (SPSS, Inc., Chicago, IL, USA). Survival curves were created by KaplaneMeier method and compared with the log-rank test. A multivariable analysis by gender, age, ECOG score, tumor location, clinical T and N stages, the radiotherapy dose of GTV and CTV, regimens and cycles of concurrent chemotherapy, and tumor response to treatment was performed using the Cox proportional hazards model. A two-tailed p value of less than 0.05 was considered statistically significant.
Results
Patient characteristics
From September 1, 2008 to December 31, 2015, a total of 132 consecutively treated patients at our institute, with a definite intent to receive chemoradiotherapy, were reviewed. Sixty patients fulfilled the inclusion criteria, of which 41 were treated with NAC-CRT and 19 were treated with CRT-alone. Patient characteristics were well balanced between the NAC-CRT and CRT-alone groups except for the ECOG scores ( p ¼ 0.007) ( Table 1) .
Chemotherapy, chemoradiotherapy and tumor response
For patients treated with NAC-CRT, a total of 89 cycles of NAC were delivered (median 2, range 1e3). The regimens of NAC included platinum plus fluorouracil in five patients; platinum plus taxane in 35 patients, and a single regimen with taxane in one patient (the cycles of the single regimen were calculated in terms of weekly dose intensity). The tumor response to NAC included 11 patients (26.8%) with PR, 25 (61.0%) with SD, 5 (12.2%) with PD, and no patients had CR.
All patients that were enrolled were treated with CRT; a total of 103 cycles of concurrent chemotherapy were delivered (median 2, range 1e2). The regimens of concurrent chemotherapy included platinum plus fluorouracil in 16 patients, platinum plus taxane in 36 patients and single regimens in eight patients (one with taxane, two with Capecitabine, and five with platinum). After completion of CRT, 21 patients achieved CR (14 in NAC-CRT and seven in CRT-alone, respectively), 30 had PR (19 and 11, respectively), six maintained SD (five and one, respectively), and three patients in the NAC-CRT group developed PD ( Table 2) .
The short-term tumor response to NAC was considered correlated with tumor response to CRT in patients treated with NAC-CRT ( p < 0.001) ( Table 3 ).
Survival
At the latest follow-up, the median follow-up time was 14 months (range, 2e97 months). Twenty-two (70.9%) patients had locoregional recurrence, three (9.7%) patients developed distant metastasis, and six (19.4%) patients regressed with local and distant failure. Twenty-nine (18 in NAC-CRT and 11 in CRT-alone) patients had succumbed to disease with locoregional or distant failure, one patient died of radiation pneumonitis, one patient died from unknown reason, and 29 patients remained alive.
Considering all the patients at 1 and 2 years, the OS was 64.9% and 40.5%, respectively, the LFFS was 58.6% and 52.0%, and the DFFS was 85.7% and 79.3% (Table 2 ). The OS, LFFS, and DFFS between the NAC-CRT and CRT-alone treatment groups were not significantly different (Figs. 1e3) . Even after the application of stratified analysis according to the T or N or clinical staging, the survival was not significantly different between the NAC-CRT and CRT-alone treatment groups. Univariate and multivariate analyses indicated that the cycles of concurrent chemotherapy and short-term tumor response to CRT were the only two significant factors that influenced OS and LFFS (Table 4 , Figs. 4 and 5) . Patients with CR to CRT had a better OS and LFFS than patients with PR, SD, or PD (Figs. 4 and 5) , while, there was no difference among the latter three groups. The short-term response to CRT was a significant factor for OS and LFFS. In the current study there was no prognostic factor that affected DFFS, which may be due to the few cases (only nine patients) who developed only distant failure (Table 4) . 4. Discussion The famous TAX 323 and 324 trials demonstrated that NAC produced superior survival in patients with squamous cell carcinoma of the head and neck (SCCHN) who received definitive chemoradiotherapy. 29, 30 However, several subsequent similar studies could not reproduce the results. 31, 32 This leads us to question the efficacy of NAC in ESCC patients who were treated with definitive CRT. To date, there is no prospective randomized clinical trial that has been able to prove the benefit of NAC in ESCC patients treated with definitive CRT. Recently, there were two small-sample retrospective studies that proved that adding NAC to definitive CRT would improve the survival of patients with local advanced disease (clinical stage T4 or clinical stage III and IVA). 11, 33 However, in the current study, whether we analyzed the data according to the T stage or N stage or the clinical stage, NAC did not improve patients' survival when compared with CRT-alone. Rational explanations for the discrepancy may include: 1) The enrolled patients in the current study included clinical stages T1-T4, and the patients with early-stage disease (T1-2) may not benefit from NAC, 34 and 2) The regimens of NAC in the retrospective studies were not uniform and lacked necessary intensity and efficacy. The OR of the NAC group in the current study was low, at 26.8% of patients with PR and no patients achieved CR. Furthermore, analysis in the subgroups demonstrated that the better the response to NAC the better was the clinical response to the subsequent CRT and the better long term survival would be achieved (Table 3 ). This is very important for clinical decision making, knowing that the response to induction therapy may be able to select patients for Fig. 3 . Distant failure-free survival for chemoradiotherapy alone (CRT) and neoadjuvant chemotherapy combined with CRT (NAC-CRT). conservative treatment without compromising their overall prognosis. 35 Unfortunately, with the limited nature of the retrospective study and small sample size in the current study, we could not extend our investigation to explore the potential reasons for this correlation.
One important hypothesis for the action of NAC is that it eliminates micrometastasis and reduces distant failure. However, as shown in the current study (Table 2) , of the patients who failed treatment, those with only distant failure made up only 12.5%, with no significant difference between the NAC-CRT and CRT-alone groups. This suggests that patients with ESCC treated with CRT do not have improved DFFS from NAC treatment when using the current popular chemotherapy regimens. More effective chemotherapy regimens may improve the efficacy of NAC. In support of this idea, Satake 18 and his co-workers conducted a prospective, multicenter clinical study of NAC-CRT with intensive chemotherapy regimens of docetaxel, cisplatin and fluorouracil in patients with locally advanced esophageal carcinoma that demonstrated efficacy by showing improved progress-free survival and 3-year survival.
Locoregional recurrence, which presents frequently with symptoms of dysphagia and seriously affects the quality of life, was the major failure pattern in esophageal cancer treated with definitive chemoradiation therapy. 36, 37 Kelsen et al. found that preoperative chemotherapy could not result in a locoregional control benefit only after an R0 resection. 7 In patients who received R1 or R2 or were non-resected, even with added post-operative chemoradiotherapy which was similar to definitive CRT as an initial treatment method in esophageal cancer, the benefit of locoregional control disappeared. In the present study, whether in the NAC-CRT or the CRT-alone groups, locoregional failure was still the main failure pattern, at 76.1% and 60%, respectively. It was disappointing for us to find that the locoregional failure after NAC-CRT was worse than in the CRT-alone group, although the difference was not significant. This result indicated that neoadjuvant chemotherapy could not improve locoregional control, 18 but may result in inferior local control due to the delay of RT. In other word, timely radiation treatment might be more beneficial to reduce the local recurrence rate than NAC. 38 The short term response to CRT is one of the important predicting prognostic factors in several kinds of cancer treated with radiotherapy. The current study showed that whether NAC-CRT or CRT-alone treatments were used, patients with CR after CRT would achieve a better survival than patients with non-PCR (Figs. 4 and 5) . This was similar to the result reported by Adenis. 39 The survival in the PR, SD, and PD groups was poor, and there was no statistically significant difference among them. This indicates that the aggressive adjuvant treatment for patients with a poor response to definitive CRT should be executed. 40 The optimum radiotherapy dose to the GTV of ESCC, especially when combined with concurrent chemotherapy, has not been standardized. 41 Recently, an expert review considered that higher radiotherapy dose (>60 Gy) to the GTV achieved advantages not only in LFFS and DFFS but also in OS. 42 As demonstrated in the current study, the higher the GTV doses, the better were the LFFS results. 43 However, as the INT 0123 trial reported, 44 this advantage did not make for an OS advantage in either the NAC-CRT or the CRT-alone groups in the current study. This implies that a 50 Gy radiation dose to the GTV was efficient when combined with concurrent chemotherapy in esophageal cancer patients. 45 In conclusion, the current study demonstrated that adding a prevalent neoadjuvant chemotherapy regimen cannot prolong survival in ESCC patients treated with definitive CRT. Limited by the study's retrospective nature, its results need further clinical trials to be confirmed.
